Emphysematous changes and lower levels of plasma irisin are associated with bronchiolitis obliterans syndrome after bilateral living-donor lobar lung transplantation.
Chronic lung allograft dysfunction
Emphysema
Irisin
Living-donor
Lung transplantation
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
14
01
2021
accepted:
19
05
2021
pubmed:
13
7
2021
medline:
2
2
2022
entrez:
12
7
2021
Statut:
ppublish
Résumé
Decreased irisin levels may be associated with the development of emphysema. Similarly, emphysematous changes may develop in patients with chronic lung allograft dysfunction (CLAD) after living-donor lobar lung transplantation (LDLLT). We investigated the severity of emphysematous changes and the relationship between irisin levels and CLAD after bilateral LDLLT and cadaveric lung transplantation (CLT). The subjects of this retrospective study were 59 recipients of bilateral LDLLT (n = 31) or CLT (n = 28), divided into a non-CLAD group (n = 41), a LDLLT-CLAD group (n = 11), and a CLT-CLAD group (n = 7). We compared the severity of emphysematous changes, the skeletal muscle mass, and the plasma irisin levels among the groups. The emphysematous changes were significantly more severe in the LDLLT-CLAD and CLT-CLAD groups (p = 0.046 and 0.036), especially in patients with bronchiolitis obliterans syndrome (BOS), than in the non-CLAD group. Although the skeletal muscle mass was similar in all the groups, the plasma irisin levels were significantly lower in the LDLLT-CLAD group (p = 0.022), especially in the patients with BOS after LDLLT, than in the non-CLAD group. Emphysematous changes and lower levels of plasma irisin were associated with CLAD, especially in patients with BOS, after bilateral LDLLT.
Identifiants
pubmed: 34251508
doi: 10.1007/s00595-021-02339-w
pii: 10.1007/s00595-021-02339-w
doi:
Substances chimiques
Biomarkers
0
FNDC5 protein, human
0
Fibronectins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
294-305Subventions
Organisme : Japan Society for the Promotion of Science
ID : Grant no. 19K09305 and 20K1774702
Informations de copyright
© 2021. Springer Nature Singapore Pte Ltd.
Références
Starnes VA, Bowdish ME, Woo MS, Barbers RG, Schenkel FA, Horn MV, et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg. 2004;127(1):114–22.
doi: 10.1016/j.jtcvs.2003.07.042
Date H, Sato M, Aoyama A, Yamada T, Mizota T, Kinoshita H, et al. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patientsdagger. Eur J Cardiothorac Surg. 2015;47(6):967–72 (discussion 72-3).
doi: 10.1093/ejcts/ezu350
Sugimoto S, Yamamoto H, Kurosaki T, Otani S, Okazaki M, Yamane M, et al. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience. Surg Today. 2019;49(8):686–93.
doi: 10.1007/s00595-019-01782-0
Yamamoto H, Sugimoto S, Tanaka S, Kurosaki T, Otani S, Yamane M, et al. A single-nucleotide polymorphism in a gene modulating glucocorticoid sensitivity is associated with the decline in total lung capacity after lung transplantation. Surg Today. 2018;49(3):268–74.
doi: 10.1007/s00595-018-1717-9
Miyamoto E, Chen F, Aoyama A, Sato M, Yamada T, Date H. Unilateral chronic lung allograft dysfunction is a characteristic of bilateral living-donor lobar lung transplantation. Eur J Cardiothorac Surg. 2015;48(3):463–9.
doi: 10.1093/ejcts/ezu463
Sugimoto S, Otani S, Ohki T, Kurosaki T, Miyoshi K, Yamane M, et al. Lung retransplantation in an adult 13 years after single lobar transplant in childhood. Gen Thorac Cardiovasc Surg. 2017;65:539–41.
doi: 10.1007/s11748-016-0732-2
Eberlein M, Permutt S, Chahla MF, Bolukbas S, Nathan SD, Shlobin OA, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest. 2012;141(2):451–60.
doi: 10.1378/chest.11-0767
Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transpl. 2019;38(5):493–503.
doi: 10.1016/j.healun.2019.03.009
Ijiri N, Kanazawa H, Asai K, Watanabe T, Hirata K. Irisin, a newly discovered myokine, is a novel biomarker associated with physical activity in patients with chronic obstructive pulmonary disease. Respirology. 2015;20(4):612–7.
doi: 10.1111/resp.12513
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8.
doi: 10.1038/nature10777
Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene? Nature. 2012;488(7413):E9-10 (discussion E-1).
doi: 10.1038/nature11364
Arhire LI, Mihalache L, Covasa M. Irisin: a hope in understanding and managing obesity and metabolic syndrome. Front Endocrinol. 2019;10:524.
doi: 10.3389/fendo.2019.00524
Wang Z, Chen K, Han Y, Zhu H, Zhou X, Tan T, et al. Irisin protects heart against ischemia-reperfusion injury through a SOD2-dependent mitochondria mechanism. J Cardiovasc Pharmacol. 2018;72(6):259–69.
doi: 10.1097/FJC.0000000000000608
Gonzalez-Gil AM, Elizondo-Montemayor L. The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: a review. Nutrients. 2020;12(6):1899.
doi: 10.3390/nu12061899
Sugiyama Y, Asai K, Yamada K, Kureya Y, Ijiri N, Watanabe T, et al. Decreased levels of irisin, a skeletal muscle cell-derived myokine, are related to emphysema associated with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:765–72.
doi: 10.2147/COPD.S126233
Date H, Aoe M, Nagahiro I, Sano Y, Matsubara H, Goto K, et al. How to predict forced vital capacity after living-donor lobar-lung transplantation. J Heart Lung Transpl. 2004;23(5):547–51.
doi: 10.1016/j.healun.2003.07.005
Hirano Y, Sugimoto S, Mano T, Kurosaki T, Miyoshi K, Otani S, et al. Prolonged administration of twice-daily bolus intravenous tacrolimus in the early phase after lung transplantation. Ann Transplant. 2017;22:484–92.
doi: 10.12659/AOT.904225
Sugimoto S, Yamane M, Otani S, Kurosaki T, Okahara S, Hikasa Y, et al. Airway complications have a greater impact on the outcomes of living-donor lobar lung transplantation recipients than cadaveric lung transplantation recipients. Surg Today. 2018;48(9):848–55.
doi: 10.1007/s00595-018-1663-6
Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transpl. 2005;24(10):1454–9.
doi: 10.1016/j.healun.2004.11.049
Glanville AR, Verleden GM, Todd JL, Benden C, Calabrese F, Gottlieb J, et al. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transpl. 2019;38(5):483–92.
doi: 10.1016/j.healun.2019.03.008
Shinya T, Sato S, Kato K, Gobara H, Akaki S, Date H, et al. Assessment of mean transit time in the engrafted lung with 133Xe lung ventilation scintigraphy improves diagnosis of bronchiolitis obliterans syndrome in living-donor lobar lung transplant recipients. Ann Nucl Med. 2008;22(1):31–9.
doi: 10.1007/s12149-007-0078-z
Yamamoto H, Sugimoto S, Kurosaki T, Miyoshi K, Otani S, Okazaki M, et al. Lung perfusion scintigraphy to detect chronic lung allograft dysfunction after living-donor lobar lung transplantation. Sci Rep. 2020;10(1):10595.
doi: 10.1038/s41598-020-67433-4
Xie M, Wang W, Dou S, Cui L, Xiao W. Quantitative computed tomography measurements of emphysema for diagnosing asthma-chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:953–61.
doi: 10.2147/COPD.S104484
Makino Y, Shimada Y, Hagiwara M, Kakihana M, Park J, Kajiwara N, et al. Assessment of emphysema severity as measured on three-dimensional computed tomography images for predicting respiratory complications after lung surgery. Eur J Cardiothorac Surg. 2018;54(4):671–6.
doi: 10.1093/ejcts/ezy112
Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition. 2016;32(11–12):1200–5.
doi: 10.1016/j.nut.2016.04.003
Takenaka T, Yamazaki K, Miura N, Mori R, Takeo S. The prognostic impact of tumor volume in patients with clinical Stage IA non-small cell lung cancer. J Thorac Oncol. 2016;11(7):1074–80.
doi: 10.1016/j.jtho.2016.02.005
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.
doi: 10.1038/bmt.2012.244
Royer PJ, Olivera-Botello G, Koutsokera A, Aubert JD, Bernasconi E, Tissot A, et al. Chronic lung allograft dysfunction: a systematic review of mechanisms. Transplantation. 2016;100(9):1803–14.
doi: 10.1097/TP.0000000000001215
Yamane M, Date H, Okazaki M, Toyooka S, Aoe M, Sano Y. Long-term improvement in pulmonary function after living donor lobar lung transplantation. J Heart Lung Transpl. 2007;26(7):687–92.
doi: 10.1016/j.healun.2007.04.008
Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, et al. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci. 2001;56(5):B209–17.
doi: 10.1093/gerona/56.5.B209
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61(12):1725–38.
doi: 10.1016/j.metabol.2012.09.002
Nowinska K, Jablonska K, Pawelczyk K, Piotrowska A, Partynska A, Gomulkiewicz A, et al. Expression of Irisin/FNDC5 in cancer cells and stromal fibroblasts of non-small cell lung cancer. Cancers. 2019;11(10):1538.
doi: 10.3390/cancers11101538
Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism. 2016;65(6):825–34.
doi: 10.1016/j.metabol.2016.02.006